Can TMS help with dementia? The latest research in 2026
If someone in your family has been diagnosed with Alzheimer’s or another cognitive decline condition like Dementia, you have probably already run into the wall. The medications help some people for a while. Then the options thin out, and the conversation often ends with some version of “there isn’t much else to try.”
So when people hear that transcranial magnetic stimulation is being studied for dementia, the question comes fast: does it work, and is it real?
Here is the honest answer up front. TMS is not a cure for dementia, and nothing in the research suggests it is. What the research does suggest is narrower. In some people with early to moderate Alzheimer’s, certain TMS protocols may slow how fast cognition declines, and TMS may help with symptoms that often come with dementia, like depression and low mood. Those are real, but they are not the same as a cure.
This article walks through what is actually known: where in the brain TMS is aimed, what the different treatment schedules look like, why a person’s age changes how much stimulation it takes, and where the evidence is strong versus thin.
Table of Contents
First, the part nobody should soften: TMS is not a cure
It is worth being blunt, because the topic invites overpromising.
TMS does not remove the amyloid plaques or tau tangles found in Alzheimer’s. It does not reverse the underlying disease. It cannot rebuild memories that are already gone. Any clinic that suggests otherwise is selling something the science does not support.
What TMS works on is a different layer of the problem. Dementia is partly a story about proteins damaging neurons. But the symptoms a family notices, especially early on, are also a story about brain networks that are still alive but communicating poorly. That second layer is where TMS has something to offer. The goal is to support and boostthe circuits that still work, not to undo the damage to the ones that do not.
Keeping that distinction clear is the whole game. It is the difference between a realistic conversation and a sales pitch.
What TMS actually does in the brain
TMS uses brief magnetic pulses to stimulate a targeted region of the brain. The pulses cause neurons in that area to fire, and repeated firing in the right pattern strengthens the connections between them. This is the same process behind learning and memory, sometimes summed up by the adage ‘neurons that fire together wire together’.
The technical name for that strengthening is long-term potentiation, and the broader capacity for it is called plasticity. Plasticity is the raw material TMS is trying to work with. The magnetic pulses do not insert anything into the brain. They nudge existing circuits to fire in a pattern that makes their connections a little stronger and a little more durable. Hold that idea, because it comes back when we talk about age.
Where you stimulate matters: the precuneus and the left DLPFC
TMS is not one treatment. Where you aim the coil changes what you are trying to affect, and dementia research has centered on two targets in particular.
The first is the precuneus. It sits toward the back and center of the brain, at the hub of a network the brain uses to pull memories and information together, and it is one of the first regions to lose function in Alzheimer’s. The newer precuneus trials aim here specifically to slow memory and functional decline.
The second, and the most studied single target across all the dementia work, is the left dorsolateral prefrontal cortex, usually shortened to the left DLPFC. It sits near the front of the head, above and behind the left temple. This same region is the one used in FDA-cleared TMS for depression, which is why a lot of what we know about stimulating it comes from decades of depression treatment.
The left DLPFC is involved in what clinicians call executive function: working memory, attention, planning, and holding information in mind while you use it. It also plays a role in mood regulation. Stimulation here is usually high-frequency, meaning faster pulse patterns, delivered either as standard rapid TMS or as the quicker theta-burst form described below. Because the left DLPFC sits at the intersection of thinking and mood, aiming at it can do two things at once. It may support executive function and working memory, and it may lift the depression and apathy that so often travel with dementia. That overlap is real and worth understanding, because it means some of the cognitive benefits seen in studies may run partly through improved mood rather than through memory circuits directly.
The large 2024 review from Mayo Clinic and Harvard found that the left DLPFC was the most common target across the studies, that high-frequency stimulation was the norm, and that protocols using more sessions and sometimes more than one brain site tended to do better than those using very few. Some systems, like the NeuroAD device, deliberately stimulate several sites in one course, including both prefrontal regions along with language and parietal areas, on the theory that dementia is a whole-network problem rather than a single-spot one.
What the research shows for Alzheimer’s and MCI
This is the important part, so here is the real evidence, good and bad.
The most encouraging data comes from a set of randomized, placebo-controlled trials led by Dr. Giacomo Koch that targeted the precuneus in patients with mild to moderate Alzheimer’s. In a 24-week trial of 50 patients, published in the journal Brain in 2022, the patients who received real stimulation held steady on a standard dementia rating scale while the placebo group declined. A follow-up trial of 48 patients, published in Alzheimer’s Research and Therapy in 2025, ran for a full year and hit its main goal, showing about 44 percent slower decline than placebo along with better scores on daily function and thinking. That protocol is now moving into larger studies.
Zoom out, and the picture holds up while getting more complicated. The 2024 Mayo and Harvard review pooled 143 studies and roughly 5,800 patients, with a focused analysis of 25 randomized trials in mild cognitive impairment and Alzheimer’s. Across those trials, TMS beat placebo on every standard measure of thinking, with large statistical effects. The same researchers were careful about the limits. The studies varied a lot in how they were run, and a big effect on a test score does not always translate into a change a family would notice at home. As they put it, in dementia even a small gain can be meaningful, but this is a field that is still maturing.
There is also growing interest in a faster form of TMS called intermittent theta-burst stimulation, or iTBS, which delivers a comparable dose in far less time. A 2025 randomized trial of 52 people with mild memory loss or very early Alzheimer’s used iTBS over the left prefrontal cortex and found real cognitive gains by week six. The delay is itself telling. The brain rewires gradually, so the benefit shows up later, not the same day.
And then there is the honest counterweight. A combined system that paired TMS with computer-based brain training, called NeuroAD, went before an FDA advisory panel. The panel found it safe but voted that it had not been shown to work for Alzheimer’s. It is approved in parts of Europe, in Australia, and in Israel, but it is not FDA-cleared in the United States. TMS for cognitive decline remains an investigational use here. This caveat belongs in any honest version of this conversation.
Two different goals: thinking, and mood
It helps to separate two things TMS can help with in dementia, because the evidence is stronger for one than the other.
The first goal is cognition. Here the aim is not to restore lost memory but to slow the rate of decline in memory, attention, language, and daily function. The trials above are mostly about this goal, and the benefit, where it shows up, is best described as modest and gradual.
The second goal is mood and behavior. Depression, apathy, anxiety, and poor sleep are common in dementia, and they hit quality of life hard, for the patient and for the people caring for them. This is firmer ground. TMS is FDA-cleared and well established for depression, including in older adults, and there is evidence that it can help with the depression that accompanies dementia. For a lot of families, better mood, more engagement, and better sleep is a meaningful result on its own, even setting the memory question aside. As noted earlier, because the left DLPFC is both the depression target and a thinking target, these two goals are not fully separate. Lifting mood can itself improve how well someone functions day to day.
Why age changes the math: plasticity and dose
Here is something that does not get explained often enough, and it matters for setting expectations.
Plasticity, the brain’s ability to strengthen connections in response to stimulation, is not constant across a lifetime. On average it declines with age. And the decline is not even. Some of the clearest evidence comes from the prefrontal cortex, the very region most used in cognitive and mood TMS. In one study, researchers applied iTBS to the left prefrontal cortex in healthy young adults and healthy older adults and measured the brain’s response. The young brains showed the expected plasticity signal. The older brains showed much less of it, and the people with the weakest response also tended to have weaker memory performance.
The practical takeaway is simple. An older brain often needs more stimulation to reach the same effect a younger brain gets from less. In real terms, that can mean more sessions, a higher stimulation intensity within safe limits, or ongoing maintenance rather than a one-and-done course. It is part of why dementia protocols so often include a maintenance phase, and why dosing should be set for the individual rather than copied from a younger depression patient.
Two honest caveats keep this from turning into “more is always better.” First, the age effect is not uniform. It varies by brain region and from person to person, and some older adults respond well. Second, more stimulation is not free. Intensity and total dose have to stay inside established safety limits, which is exactly the kind of judgment a clinician is there to make. The point is not to blast the brain harder. It is to recognize that the same protocol does not land the same way at 75 as it does at 35, and to plan accordingly.
Treatment schedules: from six weeks to a single day
People often picture TMS as one fixed routine, but the schedule is one of the biggest practical variables, and there are several shapes it can take.
The traditional course is daily. In depression, the standard is five sessions a week for about six weeks, somewhere around 30 to 36 sessions. Many dementia research protocols are shorter than that, often 10 to 20 daily sessions over two to four weeks, but the rhythm is the same: come in most days for a stretch of weeks.
Some precuneus trials used a two-week intensive followed by maintenance. Patients came in daily for two weeks, then dropped to weekly sessions that continued for up to a year. That maintenance piece is not an afterthought in dementia. Because the disease keeps progressing underneath the treatment, and because gains can fade without ongoing stimulation, a maintenance schedule is often part of the plan from the start rather than a fallback.
Accelerated schedules compress the work into fewer days by stacking several sessions into each day. The five-day model is the clearest example, delivering many sessions across a single week instead of spreading them over six. The trade-off is intensity of scheduling for total length.
The most compressed version is a single day. A 2026 case report tested this in Alzheimer’s patients, pairing D-cycloserine, a medication that primes the brain’s plasticity, with a series of short iTBS sessions in one clinic visit, repeated once a month for several months. It is the same logic as the accelerated approaches, pushed further.
Which schedule fits depends on the person. Stage of disease, how far they live from the clinic, how well they tolerate sitting for sessions, whether they depend on a caregiver for every trip, and the plasticity-and-age picture above all factor in. For an older adult who relies on an adult child for rides, a schedule that demands daily visits for weeks can be the single thing that makes treatment impossible, no matter how promising it looks on paper. A treatment a family cannot realistically get to is not much of a treatment, which is part of why shorter and maintenance-friendly schedules are getting so much attention for this population.
A word of caution on the single-day case report, because it deserves it. Two patients, with no comparison group and no placebo, is the weakest form of clinical evidence. It cannot tell you how much of the change came from the treatment versus chance or ordinary variation, and the authors themselves call for controlled trials. It is a reason to study the approach, not proof that it works.
Who this is and is not for
Based on the research as it stands, TMS is most worth a conversation when:
- The diagnosis is mild cognitive impairment or mild to moderate Alzheimer’s, where the evidence is strongest.
- You are looking for something to add to current care, not to replace medication or other treatment.
- Depression, apathy, or low mood are part of the picture.
- You understand this is an investigational use for cognition and want a realistic read on whether it could help.
It is probably not the right path when the dementia is advanced, when there is metal in or near the head or a history of seizures, or when the hope is for a cure or for lost abilities to return. A licensed clinician should make the call after a full review, which is exactly what a consultation is for.
Is TMS safe for an older adult?
Generally, yes, with proper screening. TMS is non-invasive. There is no anesthesia and no sedation, and the patient can go about a normal day afterward. The most common side effects are mild scalp discomfort or a short headache around the time of a session. There are none of the body-wide effects that medications can bring.
The most serious risk is a seizure, which is very rare, estimated at well under 1 in 30,000 sessions. In the 143-study review mentioned earlier, only two studies reported any seizures at all, and most were judged unrelated to the treatment. Older adults do warrant careful screening, because age, other medical conditions, implants, and multiple medications all factor in. That screening is the first step, not an afterthought, and it is also where the right target, intensity, and schedule get matched to the individual.
The bottom line
TMS is not a cure for dementia, and you should be wary of anyone who frames it as one. What the current research supports is more modest and still worth taking seriously: in earlier-stage Alzheimer’s, certain protocols may slow decline, and TMS can help with the depression and mood symptoms that so often come with dementia. The strongest single result, the precuneus trials, is genuinely encouraging. The broader evidence is positive but uneven. Targets, schedules, and dose all matter, and because plasticity changes with age, the right plan for an older adult is rarely a copy of someone else’s.
If you are weighing this for someone you love, the most useful thing is an honest conversation with a clinician who will tell you plainly whether it makes sense for the diagnosis and stage in front of you, who will match the target and schedule to the person, and who will say so if it is not a fit. That is the standard the research deserves, and it is the one we hold ourselves to.
If you have questions about whether TMS is worth considering for your family’s situation, that is what a free consultation is for.